The 10 most-anticipated drug launches of 2020
FiercePharma with assistance from EvaluatePharma, have assembled a list of the top 10 most-anticipated new drug launches of 2020 based on estimated global sales in 2024. Eight out of the ten could break the blockbuster barrier in four short year putting a new batch of heavy hitters in pharma’s ranks.
First is AstraZeneca and Daiichi Sankyo’s breast cancer conjugate Enhertu (fam-trastuzumab deruxtecan-nxki), the only entry on in the list that has gained an FDA approval so far. The HER2-positive cancer therapy shrank tumors in 61% of patients in a phase 2 trial, putting its possible revenue at a chart-topping $2.4 billion in 2024, according to Evaluat and AZ’s betting up to $7 billion on that prospect.
Rounding out the top five are drugs from Bristol-Myers Squibb, Novartis, FibroGen and Immunomedicand.
Then there’s Novartis’ inclisiran, acquired in a much-discussed $9.7 billion pickup of The Medicines Company in December.
The 10 most-anticipated drug launches of 2020
- Enhertu
- Ozanimod
- Inclisiran
- Roxadustat
- Sacituzumab govitecan
- Filgotinib
- Palforzia (AR101)
- Valoctocogene roxaparvovec
- Rimegepant
- Risdiplam
Visit FiercePharma in the link before for more information on the background of these most anticipated drugs.
Source: FiercePharma